Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alexandria Jones

Nurse Practitioner Evansville, IN Nurse Practitioner

NPI 1760034920 CMS profile 10974301

520 Mary St Ste 230, Evansville, IN 47710

Open in the dashboard

General payments

$5,476

370 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexandria Jones of Evansville, IN is reported in the CMS Open Payments database as having received $5,476 across 370 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $903 35
2024 General $848 68
2023 General $1,081 78
2022 General $1,204 83
2021 General $1,441 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexandria Jones
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Alexandria Jones were reported at $903. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Alexandria Jones Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,441 $135 $40–$426 $132
2022 $1,204 $152 $48–$470 $149
2023 $1,081 $166 $54–$529 $160
2024 $848 $173 $55–$556 $164
2025 $903 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Pharmaceuticals, Inc $974 76 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $785 47 payments
  3. Novartis Pharmaceuticals Corporation $762 99 payments
  4. Pfizer Inc. $624 48 payments
  5. Abiomed $446 4 payments
  6. E.R. Squibb & Sons, L.L.C. $343 25 payments
  7. AstraZeneca Pharmaceuticals LP $296 13 payments
  8. Merck Sharp & Dohme Corporation $256 15 payments
  9. Amgen Inc. $144 8 payments
  10. Boston Scientific Corporation $134 3 payments
  11. Other $714 32 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,476 370 payments
Products named General payments · program years 2021–2025
  1. XARELTO $974 76 payments
  2. LifeVest $785 47 payments
  3. ELIQUIS $516 42 payments
  4. ENTRESTO $341 35 payments
  5. VERQUVO $330 19 payments
  6. LEQVIO $258 40 payments
  7. CAMZYOS $257 17 payments
  8. FARXIGA $201 7 payments
  9. VYNDAQEL $194 14 payments
  10. Impella $156 1 payment
  11. Other $1,794 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,341

Median for Nurse Practitioner: 389

Drug cost

$152,305

Median for Nurse Practitioner: $21,885

Branded share of claims

31.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 78 $70,198
Repatha Sureclick Evolocumab Brand 39 $27,783
Entresto Sacubitril/Valsartan Brand 18 $25,262
Brilinta Ticagrelor Brand 13 $7,932
Farxiga Dapagliflozin Propanediol Brand 13 $6,978
Ranolazine Er Ranolazine Brand 34 $3,834
Metoprolol Succinate Generic 166 $2,077
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 133 $1,110
Atorvastatin Calcium Generic 95 $1,007
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 37 $1,000

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$66,778

Medicare's payments for the services billed

Medicare patients

893

Average age 76

Services billed

945

423 women, 470 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 65%
Arthritis 56%
Heart failure 43%
Atrial fibrillation 43%
Diabetes 39%
Chronic kidney disease 38%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $155
$155 — —
ELIQUIS
  • PFIZER INC. $77
  • E.R. Squibb & Sons, L.L.C. $61
$138 78 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $86
$86 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $74
$74 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $55
$55 18 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

370 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record